ADC Therapeutics has announced that co-founder Chris Martin is stepping away from his role as CEO of the commercial-stage biotechnology company. Joining the company is Ameet Mallik, formerly Head of Oncology at Novartis and CEO of Rafel Holdings.
Since 2015 ADC has from a private start-up to a New York Stock Exchange-listed company with more than 300 employees
Click here to read the entire article.